Nuvectis Pharma, Inc. financial data

Symbol
NVCT on Nasdaq
Location
Fort Lee, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 280% % -7.02%
Debt-to-equity 56% % 11.8%
Return On Equity -142% % 8.94%
Return On Assets -91% % 12.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25,614,896 shares 32.6%
Common Stock, Shares, Outstanding 25,639,896 shares 35.1%
Entity Public Float $50,000,000 USD -16.7%
Weighted Average Number of Shares Outstanding, Basic 22,719,057 shares 31.9%
Weighted Average Number of Shares Outstanding, Diluted 22,719,057 shares 31.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $17,563,000 USD 38.4%
General and Administrative Expense $8,843,000 USD 16.7%
Operating Income (Loss) $-26,406,000 USD -30.3%
Net Income (Loss) Attributable to Parent $-25,376,000 USD -31%
Earnings Per Share, Basic -1 USD/shares -18.1%
Earnings Per Share, Diluted -1 USD/shares -18.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $35,442,000 USD 106%
Other Assets, Current $145,000 USD 5.07%
Assets, Current $35,587,000 USD 106%
Assets $35,587,000 USD 106%
Accounts Payable, Current $6,439,000 USD 185%
Employee-related Liabilities, Current $4,998,000 USD 32.5%
Accrued Liabilities, Current $65,000 USD -77%
Liabilities, Current $11,577,000 USD 83.3%
Liabilities $11,577,000 USD 83.3%
Retained Earnings (Accumulated Deficit) $-92,373,000 USD -37.9%
Stockholders' Equity Attributable to Parent $24,010,000 USD 118%
Liabilities and Equity $35,587,000 USD 106%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-4,174,000 USD 4.22%
Net Cash Provided by (Used in) Financing Activities $15,505,000 USD 230%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 60,000,000 shares 0%
Common Stock, Shares, Issued 25,639,896 shares 35.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35,442,000 USD 106%
Deferred Tax Assets, Valuation Allowance $19,528,000 USD 34.8%
Deferred Tax Assets, Gross $19,528,000 USD 34.8%
Deferred Tax Assets, Operating Loss Carryforwards $11,616,000 USD 20.7%
Additional Paid in Capital $116,383,000 USD 49.2%
Deferred Tax Assets, Net of Valuation Allowance $0 USD